FDA rejects Xarelto for preventing stent thrombosis in ACS

06/30/2013 | Forbes · Bloomberg · Healio

The FDA rejected a request from Johnson & Johnson and Bayer AG to expand the use of their blood thinner rivaroxaban, or Xarelto, to prevent stent thrombosis in patients with acute coronary syndrome. The FDA has asked J&J's Jannsen Pharmaceuticals for more information about the drug's use in ACS patients. The agency previously declined a supplemental new drug application for general use of the drug to treat ACS.

View Full Article in:

Forbes · Bloomberg · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA